Lipocine Revives LPCN 1154 Trial After Identifying Site Anomalies

The BLOOM study aims to enroll approximately 120 participants for a 48-hour, at-home treatment regimen, with the first doses expected in the fourth quarter of 2026. Lipocine’s decision to move forward follows exploratory post-hoc analyses of their prior trial, which suggested that when data from one specific site—where investigators found a suspicious lack of the drug in 40% of blood samples—was excluded, the treatment showed sustained improvement in depressive symptoms. The company plans to mitigate these risks in the new study through tighter site selection, increased oversight, and centralized rating systems to reduce potential placebo interference.

Dr. Mahesh Patel, CEO of Lipocine, stated that the new protocol is designed to generate the robust evidence required for a potential New Drug Application under the FDA’s 505(b)(2) pathway. The company expects to fund the study using existing capital, reporting roughly $23.3 million in unrestricted cash as of June 30, 2026, with anticipated monthly expenditures of $1 million during the trial. While the previous study did not meet its primary goals, it did provide a favorable safety profile with no reported instances of severe adverse events or excessive sedation, a critical factor for a drug intended for home use.